PTC Therapeutics falls after $500 mln convertible announced

By Reuters News

** PTC Therapeutics' PTCT.O shares down 2.8% premarket on Mon to $73 as it looks to refinance convertible debt

** Warren, New Jersey-based PTCT offering privately $500 mln convertible bonds (CBs) due 2031

** Intends to use net offering proceeds for repurchases of a portion of its 1.5% CBs due 2026, and for repayment/retirement of any remaining 2026 CBs at maturity

** Also expects to repurchase its shares in amount of approx $50 mln to facilitate hedging by investors in the new CBs

** PTCT has roughly $6.2 bln market cap

** Through Fri close, stock down 1% YTD

** Avg rating of 15 analysts is "buy"; median PT $92.50, according to LSEG data

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.
 

Cryptocurrency-related content is intended solely as news and market commentary. Crypto Derivatives are not available to Retail clients registered with Capital Com (UK) Ltd.